KleinJan Gijs H, van Gennep Erik J, Postema Arnoud W, van Leeuwen Fijs W B, Buckle Tessa
Department of Urology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Interventional Molecular Imaging Laboratory, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands.
J Clin Med. 2025 Aug 29;14(17):6128. doi: 10.3390/jcm14176128.
Urologic oncological surgery increasingly makes use of robotic systems to realize precise and minimally invasive resections, convent to shorter hospital stays and faster recovery times. The dexterity gains enabled through procedures such as robot-assisted (RA) prostatectomy have helped realize significant advancements in recent years. Complementing these effects via the used of hybrid tracers that illuminate surgical targets, i.e., cancerous tissue, has helped advance the surgical decision making via enhanced visualization. A well-known example is Indocyanine green (ICG)-Technetium-99m (Tc)-nanocolloid, a hybrid extension of the radiopharmaceutical Tc-nanocolloid. These hybrid tracers provide a direct link between preoperative imaging roadmaps and intraoperative target identification, and improve efficiency, accuracy, and confidence of the urologist in procedures such as sentinel lymph node biopsy (SLNB). Receptor-targeted hybrid tracer analogues, for e.g., prostate specific membrane antigen (PSMA), are also being explored as an extension of the ongoing efforts that use radiotracers such as Tc-PSMA-I&S. Together, these efforts jointly pave the way for novel techniques in intraoperative lesion localization in other urological malignancies. This narrative review discusses the potential use of hybrid tracers in robotic oncological urology, including different imaging techniques and their applications for tumor localization for prostate, bladder, and kidney cancer.
泌尿外科肿瘤手术越来越多地使用机器人系统来实现精确和微创切除,这通常会缩短住院时间并加快恢复速度。近年来,诸如机器人辅助(RA)前列腺切除术等手术所带来的灵活性提升,推动了该领域的显著进步。通过使用能照亮手术靶点(即癌组织)的混合示踪剂来补充这些效果,有助于通过增强可视化来推进手术决策。一个著名的例子是吲哚菁绿(ICG)-锝-99m(Tc)-纳米胶体,它是放射性药物Tc-纳米胶体的一种混合延伸。这些混合示踪剂在术前成像路线图和术中靶点识别之间建立了直接联系,并提高了泌尿外科医生在诸如前哨淋巴结活检(SLNB)等手术中的效率、准确性和信心。受体靶向混合示踪剂类似物,例如前列腺特异性膜抗原(PSMA),也正在作为使用诸如Tc-PSMA-I&S等放射性示踪剂的持续努力的延伸而被探索。这些努力共同为其他泌尿外科恶性肿瘤术中病变定位的新技术铺平了道路。这篇叙述性综述讨论了混合示踪剂在机器人肿瘤泌尿外科中的潜在应用,包括不同的成像技术及其在前列腺癌、膀胱癌和肾癌肿瘤定位中的应用。